Watch List: Moleculin Biotech, Inc (NASDAQ:MBRX) , Moody’s Corporation (NYSE:MCO)

On 4/6/2017, Shares of Moleculin Biotech, Inc (NASDAQ:MBRX) closed at $0.85 in last trading day. After noting the initial trading entry at $0.96, it reached to a day’s high of $0.96 and moved to a day’s low of $0.85. The recent daily volume was 996.53 thousand as contrast to it’s an average volume of 901.57 thousand.

Technical Indicators:

The last close of the Moleculin Biotech, Inc stock reflects that it traded -23.34% from its 50-day moving average of $1.11. The stock traded below -65.92% to its 200-day MA of $2.49. Furthermore, it moved lower -91.13% from its 52-week high of $9.58 and +0.59% up from $0.85, which is 52-week low of the stock.

Moleculin Biotech, Inc.’s (MBRX) moved with shift of -21.30% in the past week. Over the last three months, the shares of the company have changed -61.01% and performed -85.31% over the last six months. The stock currently has Monthly Volatility of 10.17% and Weekly Volatility of 11.31%.

April 3, 2017 Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center (“MD Anderson”),  announced its financial and operating results for the fourth quarter and year ended December 31, 2016.

2016 Accomplishments & Recent Highlights:


Received Orphan Drug Designation for Annamycin by the U.S. Food and Drug Administration (“FDA”) for the treatment of acute myeloid leukemia (“AML”). The FDA grants orphan drug designation to drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including tax credits for qualified clinical trial costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval;

Moody’s Corporation (NYSE:MCO) finalized the last transaction at value of $113.34, with a daily change of +0.24% or +0.27 points. The company maintained volume of 936.51 thousand shares. In past trading day, the stock hit the maximum price of $113.68 and touched to minimum value of $111.99. It has a market cap of $ 21.63B.

Technical Indicators:

As of last trade close, the stock is trading  downside -0.64% from its one year high of $114.07 and moved +29.83% upward from $87.30, which is one year low of the stock.

The stock traded above +0.97% from its 50-day moving average of $112.25. Furthermore, the stock moved up +8.29% to its 200-day MA of $ 104.66.

During the last month, Moody’s Corporation’s (MCO) has changed 0.59% and performed 5.23% over the last 6 months. The mean rating score for this stock is at 2.70. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.29% in recent month and observed Weekly Volatility of 1.65%.

Moody’s Corporation provides credit ratings; and credit, capital markets, and economic related research, data, and analytical tools worldwide. It operates through two segments, Moody’s Investors Service and Moody’s Analytics. The Moody’s Investors Service segment publishes credit ratings on various debt obligations and entities that issue such obligations comprising various corporate and governmental obligations, structured finance securities, and commercial paper programs. This segment provides ratings in approximately 120 countries. Its ratings are disseminated through press releases to the public through print and electronic media, including the Internet and real-time information systems for use by securities traders and investors. As of December 31, 2016, this segment had ratings relationships with approximately 11,000 corporate issuers and approximately 18,000 public finance issuers. It also rated and monitored ratings on approximately 64,000 structured finance obligations. The Moody’s Analytics segment develops products and services that support financial analysis and risk management activities of institutional participants in financial markets; and distributes research and data, such as research on debt issuers, industry studies, and commentary on topical credit related events. This segment also offers economic research, and credit data and analytical tools; software solutions and related risk management services; and outsourced research and analytical services with financial training and certification programs. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody’s Corporation in September 2000. Moody’s Corporation was founded in 1900 and is headquartered in New York, New York.


Leave a Reply

Your email address will not be published. Required fields are marked *